Avastin Approved For Second-Line CRC
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech's Avastin gained approval June 20 for use in second-line treatment of metastatic colorectal cancer as an adjunct to chemotherapy, FDA said